RE:RE:RE:RE:RE:RE:RE:RE:What are we getting for $650,000?oats wrote: kidl,
Whether you are a shareholder or not, I tend to think you are, you need to find something else to do with your time because if you keep watching this on a minute by minute or hour by hour basis, you will always find reason to get distracted from what they are trying to accomplish.
I will say it again, you, along with many others, do not understand what this company is all about. You have no idea what this company needs to do to transition to the biopharma space and I get the feeling that you don't want to understand it, which is fine. Just realize that Ceapro will not always act in way that will make you happy, there is plenty of proof of that but I would rather place my reliance on Gilles Gagnon to create the opportunity that yourself. No offense, just logic, I will take the brick by brick approach any day of the week, month or year.
Oats, kid wrote a very good piece several posts back and you should be objective and open to differing opinions. He merely stated that the increase in marketing expenses, relative to what it is now (near nil), to get into retail cosmetics will be significant and suck any profitability likely for the next one or two years.
Ceapro was already on the correct path to transitioning into a high growth and high reward biopharm with its new plant and products coming in the development pipeline. Just need to stay the course and 2019 would likely startbto pay off. But to tread in the big dog world of retail end user cosmetics is a risky proposition and runs counter to the company's core strengths as a R&D and efficient manufacturer.